Background: The new ACS screening mammography guidelines suggest that only women with an above average risk require mammography screening between ages 40-44 (≥15% lifetime risk of breast cancer and/or ≥5% risk of BRCA mutation). In addition, the ACS recommends yearly MRI if the lifetime risk is ≥20%. We previously found that 50% of women ages 40-44 who were evaluated at an academic breast surgery practice would be eligible for mammograms, MRI, and/or genetic testing. Here, we sought to determine these numbers at a community breast imaging center, which we assumed would be a cohort more representative of the general population. Methods: Under IRB approval, we reviewed a database from 10/1/2015 - 12/28/2015 of patient-reported risk factors and family history at a community breast imaging center. We excluded all men, and women with a history of breast cancer. Using Tyrer Cuzick, Claus, or BRCAPRO, those with a ≥15% lifetime risk of breast cancer or ≥5% risk of BRCA mutation (eligible for genetic testing) were considered above average risk. Those with a ≥20% lifetime risk were also eligible for screening MRI. We assessed these results in Jewish and non-Jewish women. Results: 7357 women age ≥40 years without breast cancer were evaluated. Of these, 909 (12.4%) were ages 40-44 and constitute our cohort. Risk assessment identified 485 women (53.4%) who were eligible for mammography. Conclusions: At this community breast imaging center, 53.4% of women ages 40-44 would have been eligible for screening mammography. These numbers were higher in Jewish women. Thus, it is critical that women ages 40-44 have formal risk assessment, in order to identify those who would qualify for screening mammography, screening MRI, and genetic testing.